ABSTRACT
Severe sepsis and septic shock are leading causes of morbidity and mortality in the pediatric population. A large epidemiological study estimated 0.56 cases per 1000 children, or 42,364 cases per year in the United States.
(1) Infants have the highest incidence (5.16 per 1,000) and sepsis is the 4 th cause of death; children are less affected (5.16 vs 0.20 per 1000), but sepsis is the 2 nd cause of death in this age group. The overall hospital mortality rate in this study was 10.3%. (2) In Italy, sepsis, severe sepsis and septic shock represent 7.9%, 1.6% and 2.1% of pediatric intensive care unit (PICU) admissions. Mortality for septic shock is 62.5%. (3) Sepsis in the pediatric population is a major challenge and an area of paramount importance. The Surviving Sepsis Campaign guidelines of 2004 and 2008 includes a section named "pediatric consideration". (4) Unlike what is suggested for the adult population, recombinant human activated protein C (rhAPC) is contraindicated in children with a moderate evidence level. Given the beneficial effects of rhAPC in adult septic patients, although much controversy exists on this subject, (5) a multicentric phase III trial was undertaken to assess rhAPC effectiveness in pediatric patients, the RESOLVE study. (6) That trial was stopped prematurely for futility: 477 patients were randomized to receive either rhAPC or placebo. There was no difference in the primary endpoint, Composite Time to Complete Organ Failure Resolution (CTCOFR) and in the secondary endpoints, i.e., 28-day mortality and major amputations. There were numerically more (although not statistically significant) central nervous system (CNS) bleeding events in the rhAPC group during infusion (5 vs 1, p=0.10) and the 28-day period (11 vs 5, p=0.13). There were signiåcantly more study-drug-related serious adverse events and serious bleeding events during the infusion and 28-day periods in the rhAPC group. Long before rhAPC was considered for use in pediatric patients, case reports appeared on the safe administration of protein C zymogen (PC) in septic children with congenital or acquired PC deficiency. (7) In our paper, we conducted a systemic review of currently available data on PC use in the literature, updated to January 2009. Protein C and synonymous terms were used to search the literature using different Medical Databases (PubMed, Embase, Google Scholar) and the 'snowballing' technique was applied. Experts in this field were also contacted to retrieve further published papers on PC. No language restriction was applied. Papers were included in this review if at least one patient less than 18 years of age was treated with PC. A total number of 13 case reports (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and a dose-finding study (20) were found on the use of PC in the PICU, as shown in table 1. In 118 treated children, the only complication reported was a mild allergic reaction (11) and no bleeding complications occurred. The first study was published by Gerson et al. in 1993 (7) and reported on a case of purpura fulminans in a 13-yearold boy. The patient was administered PC in addition to fresh frozen plasma, to avoid fluid overload and to restore plasma PC activity that was markedly reduced at baseline (20-50%), to an arbitrary level >100% (100-200%). The child eventually survived, though he required amputation of 3 toes and surgical debridement of pelvic osteonecrosis. No complications were reported during or after PC use. In 1995 Rivard et al. (8) described 4 cases of meningococcal purpura fulminans treated with PC (age 3 months-15 years). All patients survived. They obtained normalization of PC plasma activity, increase of fibrinogen and decrease of D-dimer levels, data implying activation of PC to activated PC. Two patients, who were treated at a relatively later stage than the other two, required amputations, leading the authors to speculate in favor of prompt administration of the drug, when needed. Again, no adverse effects were observed. Patients received 100 units/kg body weight infused over 15-20 minutes, every 6-8 hours. This was continued until skin lesions ceased to develop and/or coagulation tests were stable. Smith et al. in 1997 (9) reported observed and expected mortality in 12 patients with meningococcal purpura fulminans. No patient died, in spite of an expected mortality from the Glasgow meningococcal septicaemia prognostic score (21) and the pediatric risk of mortality score of 80% and 57%, respectively. PC was administered within 18 hours of admission in 10 out of 12 patients. No one experienced adverse reactions to the drug. Two children required amputations, of whom one had a thrombotic cerebrovascular accident with complete recovery. Unfractionated heparin was used in 11 patients and antithrombin in one. Ettingshausen et al. in 1999 (10) treated 8 patients with meningococcal purpura fulminans who had severe acquired PC deficiency on hospital admission. Improvement or even normalization of global hemostatic parameters was achieved in all patients. Markedly elevated plasminogen activator inhibitor -1 (PAI-1) levels prior to treatment, reflecting a reduced fibrinolytic potential, decreased rapidly under PC substitution. Concomitantly, improving signs of purpura fulminans reflected by decreasing size of skin lesions, demonstrated a restoring microcirculation. Six of the eight patients survived. One patient required limb amputation; two patients, with severly diminished PC levels at admission, died because of multiorgan failure. No adverse effects were observed with the PC concentrate administration. In a case described by Clarke et al. in 2000, (11) the authors observed normalization of prothrombin time within 3 days from the first dose of PC, reduction of activated partial thromboplastin time to slightly supranormal levels and reduction of fibrinogen to normal values. The child received 100 units/kg body weight, intravenously, eight-hourly in addition to fresh frozen plasma 300 mL every 8-12 hours. His recovery was surprisingly rapid and without sequelae. At the second administration of PC, the patients experienced a blotchy, transient erythematous rash without associated cardiovascular instability. To the best of our knowledge, this is the only side effect reported and associated with PC use in children or adults, among all the available published literature. In 2003, the only randomized controlled trial on PC use among the pediatric population was published by de Klein. (20) That was a well designed, phase 2, dose finding study in meningococcal septic shock. Children were randomized to receive 0, 200, 400 or 600 IU/kg/ day PC in a 4 times-a-day schedule. As alredy noted by other authors, activation of PC to activated PC (APC) was achieved. That result was significantly faster with increasing dosages of PC concentrate. The study was not adequately powered to detect a difference in mortality as an outcome. Nonetheless, expected mortality (from PRISM score) was higher than actual mortality (40 vs 23%) in the treatment (all dosage) group. De Kleijn et al. demonstrated also that PC concentration in blood is dependent on the zymogen dose administered, that supplementation in a 4-shots-a-day schedule rose and maintained increased concentrations between doses. Importantly, authors showed that with a 200 IU/Kg/day, PC concentrations were restored to normal value, higher doses raising them to supra-normal levels. De Kleijn demonstrated also that PC is effectively activated after administration, and that also activation is dose-dependent. In 2003 Fourrier et al. (14) examined the pharmacokinetic properties of combined PC and antithrombin (AT) supplementation in severe purpura fulminans, to find substantial correction of both values in the patients' plasma, that peaked at 18 and 48 hours after drug administration, respectively. They used 100 IU/kg AT as a starting bolus and 100-150 IU/kg/day for 4 days, and 100 IU/ kg PC concentrate as a starting bolus plus 100 IU/kg/day in adults and 100 IU/kg every 6 hours in children. AT and PC activities at 18 hours and 24 hours, Generation of APC does not seem to be the only mechanism involved in the PC pathway: in vitro studies have shown that EPCR-bound zymogen PC induces PAR-1 cleavage by thrombin so as to generate an anti-inflammatory signal. Therefore, EPCR appeared to switch the signaling specificity of thrombin from a cytotoxic and proinflammatory to a protective effect in cultured endothelial cells. (32) This seems to agree with animal studies that show reduced mortality from lipopolysaccharide (LPS) induced endotoxemia and enhanced survival in experimental models of peritoneal sepsis by means of a recombinant APC variant with intact signalling properties on PAR-1, but < 10% anticoagulant activity. This might allow use of higher doses of those APC variants, with beneficial effects on inflammation and markedly reduced hemorrhagic risk. (33, 34) Such observations would suggest that PC/APC anticoagulant and anti-inflammatory activities are distinct, at least in vitro and in animal models of sepsis. The extent to which this is true in clinical practice is unknown. However, it seems reasonable that some anticoagulant and profibrinolytic activity is useful to promote microvascular clot lysis and organ reperfusion. PC levels reach the lower limit of normal adult levels (60-70%) around 6-12 months of age, (35) 
Conclusion
Evidence has accumulated on the clinical relevance of the PC pathway in modulating overwhelming inflammation and preventing coagulation derangements, two key mediators of organ damage, and thus of mortality and morbidity, in sepsis.
The RESOLVE trial (6) on the use of rhAPC in septic children has yielded negative results, indicating that rhAPC is of no benefit in the pediatric population and is indeed associated with increased serious adverse events and bleeding complications.
On the contrary, PC use has long been attempted in sepsis-induced coagulopathy, especially in the context of purpura fulminans, and an improvement of coagulation parameters and of survival has been described in case reports. Its use was sometimes reported to be associated with improved survival compared to expected figures extrapolated from validated indices. To date, no serious adverse event related to PC use was described, except for a mild, transient cutaneous allergic reaction in a 17-year-old male. (11) The experience collected through these studies shows that PC is safe, in that it is not associated with bleeding or severe allergic complications, and possibly useful, at least to improve the coagulation abnormalities brought about by sepsis. Unfortunately, however, all we know comes from case series or case reports or an underpowered randomized controlled study. A randomized clinical trial, adequatly powered for mortality or clinically relevant outcome, is necessary to confirm PC efficacy in the pediatric population.
